Preclinical safety and biodistribution of adenovirus-based cancer vaccines after intradermal delivery.

@article{Plog2006PreclinicalSA,
  title={Preclinical safety and biodistribution of adenovirus-based cancer vaccines after intradermal delivery.},
  author={Malinda S Plog and Cheryl A. Guyre and Bruce L. Roberts and Mark Goldberg and Judith A St George and Michael A Perricone},
  journal={Human gene therapy},
  year={2006},
  volume={17 7},
  pages={705-16}
}
The recombinant adenoviral (Ad) vector is being considered as a cancer vaccine platform because it efficiently induces immune responses to tumor antigens by intradermal immunization. The aims of this study were to evaluate the potential toxicities and biodistribution after a single dose or six weekly intradermal doses of Ad2/gp100v2 and Ad2/MART-1v2, which encode tumor-associated antigens gp100 and MelanA/MART-1, respectively. The only dose-related toxicities associated with intradermal… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Similar Papers

Loading similar papers…